Back to journals
Academic Journal

Journal of Clinical Psychopharmacology

19 Papers Indexed in Blossom

Data updated

Publication Landscape

How the 19 psychedelic papers Blossom tracks from Journal of Clinical Psychopharmacology line up by year, topic and compound. This is the journal's psychedelic-research output in Blossom's records as of July 2026; its full catalogue is much larger.

How much psychedelic research does Journal of Clinical Psychopharmacology carry?

Sourced

Tracked papers by publication year. Click a year for the running total.

5papers published in 2021

+400% vs 2020

12 published by 2021

Browse papers→

Don't read as the journal's total output: only the 19 of 19 tracked psychedelic papers from Journal of Clinical Psychopharmacology with a recorded publication date are counted, and Blossom tracks only psychedelic-relevant papers, so the full catalogue is much larger. The current year is still filling in.

What does Journal of Clinical Psychopharmacology publish on?

Sourced

Tracked papers per topic. Orange marks the largest research focus.

Depressive Disorders
15
Anxiety Disorders
10
Addiction & Substance Use
5
Safety & Risk Management
5
Schizophrenia
3
Suicidality
3
Interpersonal Functioning & Social Connectedness
3
Personality Disorders
2
Other
21

Don't read shares as adding to 100%: a paper tagged with several topics counts once per topic. These are the psychedelic-relevant papers Blossom tracks, not the journal's full catalogue.

Which compounds does Journal of Clinical Psychopharmacology cover?

Sourced

Tracked papers per compound. Orange marks the most-covered compound.

Ayahuasca
7
Psilocybin
4
Ketamine
4
DMT
3
MDMA
2
LSD
1
Esketamine
1
Ibogaine
1

Don't read shares as adding to 100%: a paper studying several compounds counts once per compound, and placebo comparator arms are not shown. These are the psychedelic-relevant papers Blossom tracks.

Research Footprint

Journal of Clinical Psychopharmacology has 19 tracked papers indexed in Blossom (2013–2026) from 95 authors, most often covering Ayahuasca, Psilocybin and Ketamine, across Depressive Disorders, Anxiety Disorders and Major Depressive Disorder (MDD).

Published Papers

Paywallindividual

An Open-Label Study of Single-Dose Psilocybin for Borderline Personality Disorder With Co-Occurring Major Depressive Disorder

This open-label pilot study (n=9) tested a single dose of psilocybin in adults with borderline personality disorder and major depressive disorder. Depressive symptoms improved over four weeks, but borderline personality disorder symptoms did not change significantly.

Published
Journal
Journal of Clinical Psychopharmacology
Authors
Grant, J. E., Boutouis, S., O’Brien, M., Avila, L., Neelapu, M., Ehsan, D.
Paywallmeta

The Therapeutic Potential of Psychedelics for Treatment-resistant Depression Reality or Hallucination? A Systematic Review

Systematic review of 15 studies (ten randomised double‑blind controlled trials and five open‑label trials) evaluating typical and atypical psychedelics in treatment‑resistant depression. The evidence indicates psychedelics can produce rapid, clinically meaningful reductions in depressive symptoms across different substance classes, supporting their potential as alternative or adjunctive treatments.

Published
Journal
Journal of Clinical Psychopharmacology
Authors
Horato, N., Dalvi-Garcia, F., Dutra, P. E. P., Nardi, A. E.
Paywallindividual

The Relationship Between Participant Pretreatment Clinical Presentation and the Quality of Psilocybin Experience: A Retrospective Analysis

In a retrospective analysis of 233 participants with treatment‑resistant depression given 1, 10 or 25 mg COMP360 psilocybin, dose was the strongest and most consistent predictor of the acute psychedelic experience, while pretreatment clinical characteristics made only modest, variable contributions (positive affect, lower generalized anxiety, higher executive function and greater personality‑disorder symptoms each influenced different experience dimensions). These results challenge the assumption that pretreatment traits are major determinants of the subjective psilocybin experience.

Published
Journal
Journal of Clinical Psychopharmacology
Authors
Kirlić, N., Atli, M., Mistry, S., Gold, M., Goodwin, G. M.
Open Accessindividual

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous RE104: A Double-Blind, Randomized, Single Ascending Dose Placebo-Controlled Study

This double-blind, randomised, placebo-controlled Phase I study (n=48) evaluates the safety, pharmacokinetics, and psychoactive effects of RE104 (psilocybin analog; Luvesilocin; a prodrug of 4-OH-DiPT) in healthy adults with prior psychedelic experience. RE104 was well tolerated up to 40 mg with no serious adverse events, and plasma levels of its active form correlated with subjective drug effect and mystical experience scores. The compound produced psilocybin-like effects with a shorter duration (3-4 hours), supporting further therapeutic investigation.

Published
Journal
Journal of Clinical Psychopharmacology
Authors
Ludbrook, G., Bryson, N., Taylor, B., Hocevar-Trnka, J., Johnson, M. W., Hirman, J., Morrish, G., Alexander, R., Pollack, M.
Paywallindividual

Effects of a Single Dose of Ayahuasca in College Students With Harmful Alcohol Use: A Single-blind, Feasibility, Proof-of-Concept Trial

In a single-blind proof-of-concept trial in 11 college students with harmful alcohol use, one dose of ayahuasca with psychological support was well tolerated and produced a short-term reduction in days drinking at 2–3 weeks that did not survive correction for multiple comparisons. The study demonstrates feasibility of the protocol and supports larger, controlled trials to assess efficacy.

Published
Journal
Journal of Clinical Psychopharmacology
Authors
Rodrigues, L. S., Rossi, G. N., Guerra, L. T. L., Maekawa, R. M., de Lima Osório, F., Bouso, J. C., Dos Santos, R. G., Santos, F. P., Paranhos, B. A. P. B., Yonamine, M., Hallak, J. E.
Paywallindividual

Interactive Effects of Ayahuasca and Cannabidiol in Social Cognition in Healthy Volunteers: A Pilot, Proof-of-Concept, Feasibility, Randomized-Controlled Trial

In a small randomised, placebo-controlled pilot trial in healthy volunteers, 600 mg oral cannabidiol given before ayahuasca produced no detectable interaction on facial emotion recognition, empathy tasks or subjective effects — both groups showed reduced reaction times and decreases in anxiety/sedation with no between-group differences. Ayahuasca with or without CBD was generally well tolerated, supporting feasibility of further, larger trials to confirm these null-interaction findings.

Published
Journal
Journal of Clinical Psychopharmacology
Authors
Rossi, G. N., Rocha, J. M., Osório, F. L., Bouso, J. C., Ona, G., De Oliveira Silveira, G., Yonamine, M., Bertozi, G., Crevelin, E. J., Queiroz, M. E. C., Crippa, J. A., Hallak, J. E., Dos Santos, R. G.

Quick Facts

Papers Indexed
19
h-Index
135
Open Access
No
Publisher
Wolters Kluwer
Country
United States
Website
Visit